Purple Biotech Ltd (PPBT) Fair Value 2026

PPBT · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

2.1 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (36/100)

Quick Summary — As of 2026-08-28, Purple Biotech Ltd (PPBT) trades at $1.68. QOC: 2.1/10. Value Trap Risk: 36/100 (LOW). 0/13 models active.

Key Facts

Ticker
PPBT
Price
$1.68
Quality Score
2.1/10
Value Trap Risk
36/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 2.1/10 signals weak fundamentals

What Fair Value Does Each Model Give PPBT?

0 Intrinsic Value Models vs. Current Price ($1.68)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Purple Biotech Ltd (PPBT) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Purple Biotech Ltd currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About PPBT?

0 of 13 models are currently active for PPBT. See which stocks rank higher →

How Does PPBT Rank in Biotechnology?

Among 625 Biotechnology stocks, PPBT ranks #619 by Quality of Company score. CirclFi's QOC score of 2.1/10 evaluates 32 fundamental signals. A score of 2.1 signals below-average fundamentals.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to life sciences company businesses. For Purple Biotech Ltd, metrics like market exclusivity window provide important context that general-purpose valuation models may underweight.

Is PPBT a Value Trap?

CirclFi's Value Trap algorithm assigns PPBT a score of 36/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Purple Biotech Ltd. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Purple Biotech Ltd scores 2.1 out of 10 on our 32-signal quality assessment, a weak rating that exhibits fundamental weaknesses that warrant careful scrutiny. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every PPBT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Purple Biotech Ltd Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

ANLAdlai Nortye Group Ltd.QOC 2.1PYPDPolyPid Ltd.QOC 2.0BLRXBioLineRx Ltd.QOC 2.2RADXRadiopharm Theranostics LimitedQOC 2.0NCELNewcelX Ltd.QOC 2.2PBMPsyence Biomedical Ltd.QOC 2.0NUVBNuvation Bio Inc.QOC 6.0ZBIOZenas BioPharma, Inc.QOC 5.0KPRXKiora Pharmaceuticals, Inc.QOC 4.5EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: ANL · PYPD · BLRX · RADX · NCEL · PBM · NUVB · ZBIO · KPRX · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to PPBT?

6 companies across all industries closest to PPBT’s Quality of Company score of 2.1/10.

VLNValens Semiconductor Ltd.QOC 2.1OMSEOMS Energy Technologies Inc.QOC 2.1LARLithium Argentina AGQOC 2.1CPOPPop Culture Group Co., LtdQOC 2.2ARQQArqit Quantum Inc.QOC 2.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: VLN · OMSE · LAR · CPOP · ARQQ · NVDA

Where Does PPBT Sit in CirclFi's Biotechnology Rankings?

PPBT is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Purple Biotech Ltd’s Valuation?

What is Purple Biotech Ltd's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Purple Biotech Ltd (PPBT). The Quality of Company score is 2.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is PPBT overvalued or undervalued right now?

At $1.68, 0 of 0 active models suggest PPBT may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Purple Biotech Ltd's business model in Biotechnology.

What does a Quality of Company score of 2.1 mean for PPBT?

Purple Biotech Ltd's QOC of 2.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on PPBT?

CirclFi analyzes PPBT with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is PPBT a value trap in 2026?

Purple Biotech Ltd's Value Trap score is 36/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Purple Biotech Ltd (PPBT) a Quality of Company score of 2.1/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/PPBT/ · Methodology
Primary sources for this PPBT valuation
  • Financial statements: Purple Biotech Ltd 10-K and 10-Q filings on SEC EDGAR (CIK 0001614744) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for PPBT as of ; valuations recomputed .